Trial Profile
A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Guretolimod (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sumitomo Pharma America; Sumitomo Pharma Oncology
- 13 Apr 2023 Status changed from recruiting to completed.
- 12 Oct 2022 Planned End Date changed from 1 Sep 2025 to 1 Jan 2023.
- 12 Oct 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2023.